Medical care of kidney transplant recipients after the first posttransplant

被引:72
作者
Djamali, Arjang
Samaniego, Millie
Muth, Brenda
Muehrer, Rebecca
Hofmann, R. Michael
Pirsch, John
Howard, Andrew
Mourad, Georges
Becker, Bryan N.
机构
[1] Univ Wisconsin, Nephrol Sect, Dept Med, Madison, WI USA
[2] Metropolitan Nephrol Assoc, Alexandria, VA USA
[3] Montpellier Med Sch, Montpellier, France
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 1卷 / 04期
关键词
D O I
10.2215/CJN.01371005
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Kidney transplantation is the treatment of choice for patients with ESRD. Despite improvements in short-term patient and graft outcomes, there has been no major improvement in long-term outcomes. The use of kidney allografts from expanded-criteria donors, polyoma virus nephropathy, underimmunosuppression, and incomplete functional recovery after rejection episodes may play a role in the lack of improvement in long-term outcomes. Other factors, including cardiovascular disease, infections, and malignancies, also shorten patient survival and therefore reduce the functional life of an allograft. There is a need for interventions that improve long-term outcomes in kidney transplant recipients. These patients are a unique subset of patients with chronic kidney disease. Therefore, interventions need to address disease progression, comorbid conditions, and patient mortality through a multifaceted approach. The Kidney Disease Outcomes Quality Initiative from the National Kidney Foundation, the European Best Practice Guidelines, and the forthcoming Kidney Disease: Improving Global Outcomes clinical practice guidelines can serve as a cornerstone of this approach. The unique aspects of chronic kidney disease in the transplant recipient require the integration of specific transplant-oriented problems into this care schema and a concrete partnership among transplant centers, community nephrologists, and primary care physicians. This article reviews the contemporary aspects of care for these patients.
引用
收藏
页码:623 / 640
页数:18
相关论文
共 198 条
[91]  
Kasiske BL, 1996, J AM SOC NEPHROL, V7, P158
[92]  
Kasiske BL, 2000, J AM SOC NEPHROL, V11, pS1
[93]   Factors associated with improvement in deceased donor renal allograft function in the 1990s [J].
Keith, DS ;
deMattos, A ;
Golconda, M ;
Prather, J ;
Cantarovich, M ;
Paraskevas, S ;
Tchervenkov, J ;
Norman, DJ .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (05) :1512-1521
[94]  
Keown P, 2001, Transplantation, V72, pS67
[95]   Tertiary hyperparathyroidism after renal transplantation: Surgical strategy [J].
Kilgo, MS ;
Pirsch, JD ;
Warner, TF ;
Starling, JR .
SURGERY, 1998, 124 (04) :677-684
[96]   Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study [J].
Knechtle, SJ ;
Pirsch, JD ;
Fechner, JH ;
Becker, BN ;
Friedl, A ;
Colvin, RB ;
Lebeck, LK ;
Chin, LT ;
Becker, YT ;
Odorico, JS ;
D'Alessandro, AM ;
Kalayoglu, M ;
Hamawya, MM ;
Hu, HZ ;
Bloom, DD ;
Sollinger, HW .
AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (06) :722-730
[97]   Hyperlipidemia in solid organ transplantation [J].
Kobashigawa, JA ;
Kasiske, BL .
TRANSPLANTATION, 1997, 63 (03) :331-338
[98]   Prevention of infection in adult travelers after solid organ transplantation [J].
Kotton, CN ;
Ryan, ET ;
Fishman, JA .
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 (01) :8-14
[99]   Long-term benefits with sirolimus-Based therapy after early cyclosporine withdrawal [J].
Kreis, H ;
Oberbauer, R ;
Campistol, JM ;
Mathew, T ;
Daloze, P ;
Schena, FP ;
Burke, JT ;
Brault, Y ;
Gioud-Paquet, M ;
Scarola, JA ;
Neylan, JF .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (03) :809-817
[100]   The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism [J].
Kruse, AE ;
Eisenberger, U ;
Frey, FJ ;
Mohaupt, MG .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (07) :1311-1314